Curewell makes majority investment in Wilmington PharmaTech

Wilmington PharmaTech announced a majority investment from Curewell. Founder and CEO Harry Li retained a significant stake and continued leading the company. The investment supports manufacturing-capacity expansion and small-molecule drug-development capabilities. Financial terms and the precise ownership percentage were not disclosed.